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Postpartum cardiomyopathy (PPCM) is a dis-
ease of unknown etiology and exposes women
to high risk of mortality after delivery. Here, we
show that female mice with a cardiomyocyte-
specific deletion of stat3 develop PPCM. In
these mice, cardiac cathepsin D (CD) expres-
sion and activity is enhanced and associated
with the generation of a cleaved antiangiogenic
and proapoptotic 16 kDa form of the nursing
hormone prolactin. Treatment with bromocrip-
tine, an inhibitior of prolactin secretion, prevents
the development of PPCM, whereas forced
myocardial generation of 16 kDa prolactin im-
pairs the cardiac capillary network and function,
thereby recapitulating the cardiac phenotype
of PPCM. Myocardial STAT3 protein levels are
reduced and serum levels of activated CD and
16 kDa prolactin are elevated in PPCM patients.
Thus, a biologically active derivative of the preg-
nancy hormone prolactin mediates PPCM, im-
plying that inhibition of prolactin release may
representanovel therapeuticstrategy forPPCM.
INTRODUCTION
Postpartum cardiomyopathy (PPCM) is a disease of un-
known etiology, characterized by an acute onset of heart
failure in women in the late stage of pregnancy up to sev-
eral months postpartum, resulting in high mortality despiteoptimal medical therapy (Elkayam et al., 2005; Reimold
and Rutherford, 2001; Sliwa et al., 2002).
In PPCM patients, serum markers of inflammation and
apoptosis are significantly elevated, which appears to
predict impaired functional status and mortality, consis-
tent with the idea that inflammation and apoptosis may
contribute to the pathogenesis of PPCM (Sliwa et al.,
2006; Sliwa et al., 2002). In line with these clinical observa-
tions, it has been shown that transgenic mice with cardiac-
specific overexpression of the a subunit of Gq develop
PPCM, which could be attenuated by pharmacological
inhibition of apoptosis (Hayakawa et al., 2003).
We noted that female mice with a homozygous or het-
erozygous cardiomyocyte-specific knockout of STAT3
(aMHC-cre+/o; stat3flox/flox: CKO; aMHC-cre+/o; stat3flox/+:
HET) develop PPCM in a dose-dependent manner (CKO >
HET). Notably, STAT3 is involved in protection of the heart
from oxidative stress by upregulation of antioxidative
enzymes such as the reactive oxygen species (ROS)
scavenging enzyme manganese superoxide dismutase
(MnSOD) (Negoro et al., 2001). STAT3 also plays an im-
portant role in promoting myocardial angiogenesis both
by paracrine and autocrine mechanisms in cardiomyo-
cytes and nonmyocytes (Bartoli et al., 2003; Hilfiker-
Kleiner et al., 2004a; Osugi et al., 2002), and it can mediate
cardiomyocyte hypertrophy (Hilfiker-Kleiner et al., 2004a;
Kunisada et al., 2000). In the present study, we used the
above genetic mouse model to investigate potential un-
derlying mechanisms, which may initiate and/or drive
PPCM. We found a detrimental link between enhanced
oxidative stress and cleavage of the pregnancy hormone
prolactin (PRL) into an antiangiogenic 16 kDa form (Corba-
cho et al., 2002; Tabruyn et al., 2003) as a major cause ofCell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc. 589
Table 1. HW:BW, Cardiac Dimensions, and Function in NT and CKO Female Mice Postpartum with or without
Treatment with BR
NP PP PP/BR
NT CKO NT CKO NT CKO
HW:BW (mg:g) 3.8 ± 0.5 3.7 ± 0.3 4.6 ± 0.5* 5.5 ± 1.2*# 4.1 ± 0.5 4.5 ± 0.7**
LVEDD (mm) 3.5 ± 0.2 3.6 ± 0.4 3.9 ± 0.2** 4.8 ± 1.0**# 3.9 ± 0.2* 3.6 ± 0.2
LVESD (mm) 2.2 ± 0.3 2.4 ± 0.5 2.7 ± 0.4** 3.8 ± 1.3**# 2.5 ± 0.1* 2.3 ± 0.3
IVSD (mm) 0.69 ± 0.07 0.69 ± 0.10 0.72 ± 0.19 0.80 ± 0.21 0.65 ± 0.06 0.62 ± 0.08
IVSS (mm) 1.1 ± 0.1 1.1 ± 0.1 1.2 ± 0.2 0.8 ± 0.4# 1.1 ± 0.1 1.1 ± 0.2
LVPWD (mm) 0.53 ± 0.11 0.50 ± 0.08 0.64 ± 0.11* 0.50 ± 0.05 0.50 ± 0.08 0.52 ± 0.08
LVPWS (mm) 0.97 ± 0.10 0.87 ± 0.12 0.98 ± 0.25 0.58 ± 0.20*# 0.90 ± 0.14 0.80 ± 0.16
FS (%) 38 ± 3 33 ± 5 32 ± 7* 14 ± 8**## 38 ± 4 36 ± 9
HR (beats/min) 350 ± 54 343 ± 74 312 ± 31 326 ± 72 300 ± 31 303 ± 54
Postpartum (PP), postpartum/BR (PP/BR), and age-matched nulli-pari (NP) females were utilized for these studies. Heart-to-body-
weight ratio (HW:BW), LV end-diastolic diameter (LVEDD), end-systolic diameter (LVESD), intraventricular septum thickness in
diastole (IVSD) or in systole (IVSS), LV posterior wall thickness in diastole (LVPWD) and systole (LVPWS), fractional shortening
(FS), and heart rate (HR) were determined by transthoracic echocardiography in sedated mice. At least five animals per group
were investigated for each parameter. Data are represented as mean ± SD, *p < 0.05, **p < 0.01 versus NT-NP, #p < 0.05, and
##p < 0.01 versus NT-PP.PPCM. Furthermore, we explored similarities between
PPCM in mice and humans and initiated a novel therapeu-
tic strategy with the PRL inhibitor bromocriptine in woman
with a high risk of developing PPCM.
RESULTS
Cardiac-Restricted Deletion of stat3 Leads to PPCM
Nulli-pari CKO (CKO-NP) and HET females (HET-NP) de-
velop normally and do not show signs of heart failure or in-
creased mortality. At the age of 6 months, cardiac function
is normal and comparable with sisters harboring two cop-
ies of the floxed stat3 allele (NT-NP) without the aMHC-
cre+/o transgene (Table 1, HET-NP, data not shown).
No pregnancy-associated cardiac phenotype or mortal-
ity was observed in 20 NT sisters (Figure 1A) or ten females
with only the cre transgene (aMHC-cre+/o: C+/+-PP; Fig-
ure 1A and Table S1, in the Supplemental Data available
with this article online). Thus, neither the floxed stat3 allele
alone nor cre alone had an adverse effect peri- and post-
partum. By contrast, physiological stresses of pregnancy,
labor, and/or nursing resulted in PPCM in all of the 53 CKO
females studied. Roughly two-thirds (37 out of 53 CKO
females versus 0 out of 20 NT-PP females, p < 0.01) had
died after the second pregnancy (Figure 1A). Notably, no
CKO female survived more than five pregnancies. In HET
females, PPCM-related death was found after three to
four deliveries (Figure 1A). Death occurred always within
the first 3 weeks after delivery. After two and four pregnan-
cies, respectively, the majority of CKO and HET females
presented signs of overt heart failure, such as generalized
edema and labored breathing. The hearts were character-
ized by four-chamber dilatation, often with thrombi in the
atria, extensive fibrosis (Figure 1B), and an increase in590 Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc.cardiomyocyte length (Table S2 and Figure S1). Echocar-
diography revealed left ventricular (LV) dilatation and de-
pressed fractional shortening in CKO-PP and HET-PP
females (Table 1 and Table S3) compared with NT-PP
females. CKO-PP females showed increased cardiac
mRNA levels of hypoxia inducible factor-1a (HIF1a) (Chi
and Karliner, 2004) and BNIP3 (Kubasiak et al., 2002) (Fig-
ure 1C) and a markedly reduced content of energy-rich
phosphates, ATP (68% ± 7%, p < 0.01 versus NT-PP),
and ADP (57% ± 10%, p < 0.01 versus NT-PP), indica-
tive for cardiac hypoxia. Cardiac apoptosis, as indicated
by an increased number of TUNEL-positive cells (cardio-
myocytes and nonmyocytes) and protein levels of acti-
vated caspase-3 (act-Casp-3), was substantially higher
in CKO-PP females compared with NT-PP females (Fig-
ures 1D and 1E) or C+/+-PP females (Figure S2).
STAT3 Is Activated in the Maternal Heart
in Pregnancy and Postpartum
In NT-Prg (day 17 of pregnancy) and NT-PP females, we
observed increased Tyr-705 phosphorylation of STAT3
(Figure 1F). As expected, cardiac STAT3 was barely de-
tectable in CKO females (Figure 1F) and STAT3 signals
were markedly reduced in the isolated cardiomyocyte-
enriched fraction, but not in the nonmyocyte fraction of
CKO-PP compared with NT-PP hearts, (Figure S2), indi-
cating that STAT3 activation in LVs from NT-PP mice is
mainly occurring in cardiomyocytes. Prolactin (PRL) se-
rum levels increased late in pregnancy and postpartum
and are known to activate STAT3 (Cataldo et al., 2000).
In fact, infusion of recombinant PRL activated STAT3 in
the heart in vivo, and addition of PRL to cultured cardio-
myocytes activated STAT3 in vitro (Figure S3).
Figure 1. PPCM in CKO-PP Mice
(A) Survival in relation to number of pregnancies of NT-PP (n = 20), C+/+-PP (n = 10), HET-PP (n = 7), and CKO-PP mice (n = 53).
(B) Representative H&E (upper panels) and picro-Sirius red (lower panels) staining in heart sections from a CKO-PP mouse (middle panels), an age-
and pregnancy-matched NT-PP mouse (left panels), or a CKO-BR mouse (right panel). Bars in upper panels, 2.5 mm; bars in lower panels, 100 mm.
Bar graph summarizes quantification of fibrosis.
(C and D) Bar graphs summarizing mRNA expression of HIF1a and BNIP3 (C) or the ratio of TUNEL positive to total number of nuclei in LVs from NT
and CKO females (D).
(E) Protein levels of act-Casp-3 in LVs from NT or CKO females.
(F) Protein levels of P-STAT3 and total STAT3 in LVs from NT or CKO mice; the bar graph summarizes the ratio of P-STAT3:STAT3 in LVs from NT
females.
In (B)–(H), four to seven mice per group were analyzed. Abbreviations: NP, nulli-pari; Prg, pregnant; PP, postpartum; and W, 4 weeks after weaning.
Data are presented as mean ± SD. *p < 0.05, **p < 0.01 versus NT-NP, ##p < 0.01 CKO-PP versus NT-PP, and xxp<0.01 CKO-BR versus CKO-PP.Cardiac Deficiency of STAT3 Does Not Affect
Pregnancy-Induced Cardiac Hypertrophy
Pregnancy induces a reversible physiological hypertrophy
of cardiomyocytes (Eghbali et al., 2005). CKO-Prg and
NT-Prg females showed a similar increase in cardiomyo-
cyte growth (cross-sectional area and length; Figure S1
and Table S2), indicative for normal Prg-induced cardiac
hypertrophy in CKO-Prg females.
Postpartum Myocardial Angiogenesis
Is Impaired in CKO Females
Physiological hypertrophy, as it is observed during preg-
nancy (Eghbali et al., 2005), requires the proportional
growth of the capillary network (Hudlicka and Brown,
1996). In NT-Prg and CKO-Prg females, the ratio of capil-
laries to cardiomyocytes increased to a similar degree(Figures 2A and 2B). This increased capillary density was
maintained in NT-PP females, although it had decreased
to prepregnancy levels in CKO-PP females (Figures 2A
and 2B). The reduction in the LV capillary density in
CKO-PP mice was paralleled with decreased expression
of VEGF (CKO-PP: mRNA, 30% ± 15%; VEGF protein:
56% ± 22% versus NT-PP, p < 0.05) and of von Wille-
brandt Factor (CKO-PP: vWF mRNA,26% ± 16% versus
NT-PP, p < 0.05).
Increased Oxidative Stress in CKO-PP Hearts
STAT3 is known to protect cardiomyocytes from oxidative
stress in part by the upregulation of the ROS scavenging
enzyme MnSOD (Negoro et al., 2001). NT-PP mice showed
a marked increase in cardiac MnSOD protein levels com-
pared to NT-NP, whereas only a moderate increase wasCell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc. 591
Figure 2. Capillary Density in the Peri- and Postpartum Heart
(A) Capillaries in LV sections of NT-NP, CKO-NP, NT-Prg, CKO-Prg, NT-PP, CKO-PP, NT-BR, and CKO-BR were identified by isolectin B4 immuno-
histochemistry (yellow). WGA marks cell membranes (red), and Hoechst stain identifies nuclei (blue) (bars, 40 mm).
(B) Bar graph summarizing capillaries per 100 cardiomyocytes in NT and CKO mice; ratios in NT-NP females were set as 100% (CKO-NP, n = 12; NT-
Prg, n = 4; CKO-Prg, n = 5; NT-PP, n = 12; CKO-PP, n = 12; NT-BR n = 11; and CKO-BR, n = 11). Similar data were obtained with CD31/WGA staining
(data not shown).
(C) In situ detection of superoxide production with dihydroethidium fluorescence staining (the oxidative dye hydroethidine is red fluorescent when
oxidized to EtBr by O2
) in LV sections of NT-PP, CKO-PP, CKO-MnTBAP, and CKO-BR females 5 days postpartum.
(D) Protein levels of MnSOD in NT and CKO mice; the bar graph summarizes MnSOD protein levels (n = 4–6 each genotype). Data are presented as
mean ± SD, *p < 0.05, **p < 0.01 versus NT-NP, #p < 0.05, ##p < 0.01 CKO-PP versus NT-PP, and xxp < 0.01 CKO-BR versus CKO-PP.observed in CKO-PP females (Figure 2D). Likewise, car-
diac MnSOD mRNA levels were higher in NT-PP than
CKO-PP females (NT-PP: +54% ± 1% versus CKO-PP,
p < 0.05). The production of ROS was enhanced in LVs
from CKO-PP compared with NT-PP females as deter-
mined by dihydroethidium fluorescence staining, (5 days
postpartum: +91% ± 32% versus NT-PP, p < 0.05, Fig-
ure 2C; and 3 weeks postpartum CKO-PP: +48% ± 23%
versus NT-PP, p < 0.05) and as determined by NADH-
stimulated superoxide production measured by electron
spin resonance spectroscopy (3 weeks postpartum:
CKO-PP: +122% ± 71% versus NT-PP, p < 0.05).
MnTBAP Attenuates PPCM in CKO Mice
We assessed whether the pharmacological suppressor
of ROS, tetrakis (4-benzoic acid) porphyrin (MnTBAP),592 Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc.a substance with catalytic activities similar to MnSOD
(Houstis et al., 2006), would prevent PPCM. In fact,
MnTBAP attenuated ROS generation in CKO females
(CKO-MnTBAP: +6%± 7% versus NT-PP, n.s.; Figure 2B),
the upregulation of activated cathepsin D (CD) and act-
Casp-3 protein, and the increase in b-myosin heavy chain
(bMHC) mRNA (Figure S4). Moreover, CKO-MnTBAP
females showed preserved cardiac capillary density
(Figure S4) and cardiac function (Table S4) and displayed
no postpartum-related mortality (0% in CKO-MnTBAP,
n = 12, after two subsequent pregnancies). Despite pre-
served cardiac function, MnTBAP did not prevent the LV
dilatation (Table S4) and the upregulation of matrix metal-
loproteinase 3 (MMP3) mRNA (Figure S4), indicating only
a partial suppression of the PPCM phenotype in CKO
females.
Figure 3. PRL Cleavage Assay and CD Expression and Activity in LVs of NT and CKO Females
(A) Protein levels of 23 and 16 kDa PRL in NT-Prg, CKO-Prg, NT-PP, CKO-PP, or CKO-NP LV supernatant after incubation with recombinant PRL for
0 hr (P0) or for 2 hr (P2) in the absence or presence of pepstatin A (Pe) or (B) after preabsorbtion with a neutralizing CD antibody (PCD) or unspecific IgG
antibody (PIgG) prior to incubation for 2 hr.
(C) LV protein levels of CD (CD Msc, mature single-chain; CD LM, large chain of mature double-chain); the bar graph summarizes CD protein levels,
and (D) anti-CD staining (brown) and nuclear staining with hematoxylin (blue) in LV sections form in NT, CKO and HET females, NP, and PP. IgG served
as control for anti-CD specificity. Right panels demonstrate extracellular localization (arrows point to interstitium) of CD in CKO-PP by immunofluo-
rescence staining in a larger magnification (CD, green; WGA, red; and Hoechst, blue); bars, 50 mm.
(E) Bar graph summarizing CD activity in NT and CKO LV supernatant.
(F) H&E-stained LV section from NT-NP mice infected with CD-Ad in the presence (CD-Ad-PRL) or absence (CD-Ad-NaCl) of high levels of recombi-
nant PRL.
(G) Protein levels of CD, 16 kDa PRL, and act-Casp-3 in LVs from CD-Ad-NaCl, lacZ-Ad-NaCl, and CD-Ad-PRL mice. NP, nulli-pari; PP, postpartum.
All data are from n = 4–6 individuals per genotype and are presented as mean ±SD. *p < 0.05, **p < 0.01 versus NT-NP, and #p < 0.05 CKO-PP or HET-
PP versus NT-PP. HET-PP mice after four litters.CD-Dependent Cleavage of PRL in CKO-PP Hearts
PRL, a dominant hormone in pregnancy and early post-
partum, can exert opposing effects on angiogenesis de-
pending on proteolytic processing of the proangiogenic
full-length 23 kDa PRL into an antiangiogenic 16 kDa
form (Corbacho et al., 2002; Tabruyn et al., 2003). An an-
tibody recognizing both forms of PRL (Lkhider et al., 2004)
showed immunoreactivity in LV sections of nursing CKO-
PP and NT-PP females, but not in LV sections of NT-NP or
CKO-NP females (Figure S5), whereas in western blot
analysis, neither this nor other commercially available an-
tibodies against PRL revealed reproducible quantitative or
qualitative results. However, in an ex vivo assay (Lkhider
et al., 2004) using supernatant of minced LV tissue fromCKO-PP females, a high cleavage activity for recombinant
PRL into the 16 kDa form was observed, whereas no
cleaved 16 kDa PRL was generated from LV tissue ex-
tracts of CKO-NP, NT-PP, CKO-Prg, or NT-Prg mice
(Figure 3A).
Among the proteolytic enzymes known to process PRL,
CD very efficiently cleaves PRL into its 16 kDa form (Cor-
bacho et al., 2002; Tabruyn et al., 2003). In fact, the PRL
cleaving activity of CKO-PP LV supernatant was attenu-
ated by preincubation with the CD inhibitor pepstatin A
(Lkhider et al., 2004) or by preabsorbing the supernatant
with a CD neutralizing antibody (Figures 3A and 3B), impli-
cating that CD is the major PRL cleavage enzyme in
CKO-PP hearts.Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc. 593
Figure 4. Adenoviral Expression of
16 kDa PRL in Mouse LVs
(A) Protein expression of 16 kDa PRL, VEGF,
and act-Casp-3 in LVs from NT females or
controls (C) infected with 16K-Ad or lacZ-Ad.
(B) Bar graphs display reduced percentage of
FS and LV dilatation in NT-NP females infected
with 16K-Ad (n = 5) compared with females
infected with lacZ-Ad (n = 5).
(C) Anti-PRL staining (brown, [a]) and IgG con-
trol (b) in 16K-Ad-infected LV sections. Anti-
PRL (c) or lacZ (d) staining in lacZ-Ad-infected
LV tissue sections (bars, 100 mm).
(D) Capillary density identified by staining with
isolectin B4 (yellow), WGA (red), and Hoechst
(blue) in LV sections from 16K-Ad (a) or lacZ-
Ad NT-NP females (b) (bars, 50 mm). Data are
presented as mean ± SD, *p < 0.05.Oxidative stress promotes the release of CD from lyso-
somes into the cytosol in cardiomyocytes (Corbacho
et al., 2002; Roberg and Ollinger, 1998). Cardiac protein
levels of the active single chain mature form of CD (CD
Msc) were markedly upregulated in CKO-PP females com-
pared with those in NT-PP, NT-NP, and CKO-NP females
(Figure 3C), but expression of activated CD was attenuated
in CKO-MnTBAP females (Figure S4). LV sections from
NT-NP and CKO-NP females showed weak staining for
CD in cardiomyocytes (Figure 3D), whereas marked stain-
ing for CD was observed in cardiomyocytes and the LV
interstitium of CKO-PP and HET-PP females (Figure 3D).
CD cleavage activity was substantially enhanced in super-
natants of minced LVs of CKO-PP females compared with
CKO-NP or NT-PP females (Figure 3E). Cultured cardio-
myocytes infected with a CD expressing adenovirus (CD-
Ad) released active CD forms into the cell culture medium,
which processed 23 kDa PRL into 16 kDa PRL (Figure S6).
Prolactin Promotes Cardiac Injury in CD
Overexpressing Hearts
We analyzed the effect of locally produced CD in the pres-
ence of high systemic PRL levels by injecting a CD ex-
pressing adenovirus (CD-Ad) into hearts of NT-PRL or
control females (NT-NaCl). Seven days after infection
with CD-Ad, NT-PRL mice showed severe cardiac dam-
age (Figure 3F), including elevated levels of act-Casp-3
(Figure 3G) and enhanced mortality compared with NT-
NaCl mice infected with CD-Ad (mortality: CD-Ad in NT-
PRL, 33%, n = 9; versus 0% in CD-Ad in NT-NaCl, n =
7). Enhanced cardiac CD expression was detected in all
CD-Ad-infected mice. PRL, notably mainly the cleaved
16 kDa form, could only be detected in females that594 Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc.were chronically infused with recombinant 23 kDa PRL
(Figure 3G).
16 kDa PRL Decreases Myocardial Capillary
Density and Reduces Cardiac Function
Independent of Pregnancy
To examine the effect of the 16 kDa PRL in the heart, we in-
jected adenoviral vectors expressing human 16 kDa PRL
(16K-Ad) or lacZ (lacZ-Ad) as control into the LV wall of
NT-NP females. Two weeks after infection, persistent car-
diac expression of 16 kDa PRL was observed in 16K-Ad-
infected females that was associated with LV dilatation
and decreased cardiac function compared with lacZ-Ad-
infected females (Figures 4A–4C). The 16 kDa PRL expres-
sion was paralleled by decreased cardiac capillary density
(31%±12%, p < 0.05, Figure 4D), reduced VEGF expres-
sion, and increased protein levels of act-Casp-3 (Fig-
ure 4A). Infection with 16K-Ad did not alter the LV:BW ratio
or the cardiomyocyte CSA (Figure S6). In cultured cardio-
myocytes, survival was similar after infection with the
16K-Ad or the lacZ-Ad (Figure S6). However, 16K-Ad infec-
tion of cultured cardiomyocytes impaired their metabolic
activity (Figure S6).
Chronic infusion (3 weeks) of recombinant full-length
23 kDa PRL in NT-NP and CKO-NP (NT-PRL and CKO-PRL)
in absence of postpartum-associated stress did not affect
cardiac function and survival (Table S5). Activation of
STAT5 was observed in LVs of NT-PRL and CKO-PRL
mice (Figure S3), in line with studies implicating STAT5
as a preferential target for PRL (Cataldo et al., 2000). In ad-
dition, stimulation with 23 kDa PRL enhanced the activa-
tion of STAT3 in NT-NP hearts in vivo and in cultured car-
diomyocytes in vitro (Figure S3). In line with described
proangiogenic effects of 23 kDa PRL (Corbacho et al.,
2002), the myocardial capillary density was slightly en-
hanced in NT-PRL and CKO-PRL females (Table S5).
Bromocriptine, an Inhibitor of PRL Secretion,
Prevents PPCM in CKO Females
The role of PRL for the development of PPCM was tested
by preventing its release from the pituitary glands using
bromocriptine (BR), a dopamine-D2-receptor agonist,
known to block PRL efficiently in humans (Harrison, 1979)
and mice (Nagafuchi et al., 1999). CKO (CKO-BR) and NT
(NT-BR) females were treated with BR for two consecutive
pregnancies. The efficient blockade of PRL release was
confirmed by the following observations: (1) in contrast
to NT-PP and CKO-PP females with detectable PRL anti-
gens in LV sections, LV sections from NT-BR and CKO-BR
mice were negative for PRL staining (Figure S5), (2) NT-BR
and CKO-BR were not able to nurse their offspring be-
cause pups appeared underdeveloped three days after
birth, and (c) the increased activation of STAT5, the pref-
erential target of PRL, was attenuated in CKO-BR and
NT-BR females (Figure S7).
BR prevented postpartum mortality in CKO-BR females
(mortality after two pregnancies: 0% in CKO-BR females,
n = 12 versus 70% in CKO-PP females, n = 53, p < 0.01)
and preserved postpartum angiogenesis (Figures 2A and
2B), cardiac function, and dimensions (Figure 1B, Table 1,
and Figure S8). BR also prevented cardiac fibrosis and ap-
optosis (Figures 1B, 1D, and 1E), attenuated the mRNA
expression of HIF1a and BNIP3 (Figure 1C) and bMHC
and MMP3 (Figure S8), and normalized the expression of
aMHC (Figure S8) in CKO-BR females.
BR did not reduce ROS production in the early state
(5 days postpartum) of treatment (CKO-BR: +67% ± 9%
versus CKO-PP: 91% ± 32%, n.s., Figure 2C). After 3
weeks of postpartum treatment, however, ROS produc-
tion in CKO-BR was markedly reduced (CKO-BR: +7% ±
23% versus CKO-PP 48% ± 23%, p < 0.05, Figure S8).
In NT-BR females, cardiac function, cardiac angiogenesis,
blood pressure, and heart frequency were not affected
(Table 1 and Tables S6–S8). Thus, we did not identify
direct effects of BR on the myocardium.
Decreased STAT3 Protein Levels
in the Myocardium of PPCM Patients
To explore whether STAT3 is involved in human PPCM as
well, STAT3 protein levels were quantified in LV tissue ob-
tained from PPCM patients (n = 5) at the time of transplan-
tation and compared with levels in similar LV tissues of
otherwise normal human hearts (n = 7). Figure 5A shows
reduced STAT3 protein levels in LVs from patients with
PPCM compared with normal human LVs.
Serum of Lactating Women with PPCM Displays
Increased oxLDL Levels, Enhanced Activation of CD,
and Augmented Protein Levels of the 16 kDa PRL
In the serum of lactating patients with PPCM, levels of
oxidized low-density lipoprotein (oxLDL), a marker for ox-idative stress (Weinbrenner et al., 2003), and CD activity
were enhanced compared with healthy lactating mothers
(Figures 5B and 5C). Marked levels of an antigen corre-
sponding to the 16 kDa PRL were detected by western
blot (Figure 5D) in the sera of three out of five lactating
PPCM patients with obvious cardiac dysfunction at the
time of serum sampling (mean percentage of EF, 24 ± 7).
It is important to note that the 23 kDa form of PRL was
readily detectable, whereas the 16 kDa PRL was barely
detectable in healthy lactating women (n = 5, Figure 5D).
Indication that Bromocriptine Treatment Prevents
PPCM in High-Risk Patients
Women with PPCM who recover normal cardiac function
have a high risk for recurring PPCM (Sliwa et al., 2004).
We therefore initiated a preliminary clinical study in
women who had recovered from a previous episode of
PPCM and presented with a subsequent pregnancy. Six
out of 12 women received BR in addition to standard ther-
apy up to 3 months postdelivery while six patients re-
ceived standard treatment (peripartum ejection fraction,
EF, was similar in both groups; Table S9). In patients re-
ceiving BR postdelivery, PRL serum levels, which were el-
evated more than 5-fold, returned to nonpregnant levels
within 14 days of treatment (Figure 5D) as described pre-
viously (Harrison, 1979). Three months postpartum, all six
Figure 5. Cardiac STAT3 Expression and Serum Levels of
Activated CD and Cleaved 16 kDa PRL in Patients with PPCM
(A) STAT3 protein levels in nonfailing (NF) LVs and in LVs from patients
with end-stage heart failure due to PPCM. Total actin served as loading
control.
(B) Serum levels of oxLDL in PPCM patients (n = 29) and pregnancy
matched controls (n = 21).
(C) CD activity in nursing PPCM patients (n = 5) and in pregnancy
matched healthy control women (n = 5).
(D) PRL immunoprecipitation followed by detection of 23 kDa and
16 kDa PRL in serum of nursing PPCM patients, healthy nursing
women (PP), control women (NP), and women with PPCM after a 14
days treatment with BR (PPCM/BR). Data are presented as mean ±
SD, *p < 0.05, and **p < 0.01.Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc. 595
BR-treated women had preserved or increased LV func-
tion and dimensions (Table S9) and survived the 4 month
observation period. In contrast, the EF in the non-BR-
treated (UT) group was deteriorated and three women
had died within 4 months (Table S9).
DISCUSSION
We present evidence that pregnancy-related adaptive hy-
pertrophy is associated with enhanced cardiac angiogen-
esis and that maintenance of the latter in the postpartum
phase critically depends on STAT3. The absence of car-
diomyocyte STAT3 in the postpartum heart causes in-
creased oxidative stress due to blunted induction of the
antioxidant enzyme MnSOD. As a consequence, expres-
sion and proteolytic activity of CD are increased, which
in turn, induces a detrimental conversion of the nursing
hormone PRL into its antiangiogenic 16 kDa derivative.
The generation of 16 kDa PRL greatly accelerates the neg-
ative effects of oxidative stress and activated CD. In fact,
its detrimental effects on the coronary microvasculature
promote myocardial hypoxia and apoptosis, thereby con-
tributing to the development of PPCM. Thus, we provide
evidence that enhanced activity and release of CD mech-
anistically connects the increased oxidative stress in
STAT3-deficient cardiomyocytes to the development of
PPCM. In fact, our study links cardiac processing of PRL
into an antiangiogenic and proapoptotic 16 kDa peptide
by CD to PPCM and implies that blocking the secretion
of PRL can prevent PPCM in mice. Initial clinical observa-
tions are consistent with the notion that this beneficial
effect of BR may also apply to patients with PPCM.
Enhanced myocardial capillary density is part of the
physiological hypertrophy, which the maternal heart un-
dergoes to compensate for the increased volume and
workload during pregnancy and labor. Because NT-Prg
and CKO-Prg female mice showed increased myocardial
capillary density late in pregnancy, this process seems
to be independent from cardiomyocyte STAT3. Increased
myocardial capillary density is maintained up to 3 weeks
postpartum in NT-PP females. In CKO-PP females, how-
ever, enhanced myocardial capillary density is lost in the
postpartum phase, implying a novel role of STAT3 as a
key requisite for maintaining postpartum myocardial an-
giogenesis. Failure of this process leads to hypoxia as
indicated by the increased expression of the hypoxia
marker genes HIF1a (Chi and Karliner, 2004) and BNIP3
(Kubasiak et al., 2002), a lower content of energy rich
phosphates, apoptosis, and subsequently, heart failure.
Increased hemodynamic load, occurring during preg-
nancy and labor, may promote cardiac hypoxia and oxida-
tive stress in CKO mice. However, we never observed
symptoms or death in CKO females during pregnancy or
at delivery, when hemodynamic load culminates. Likewise,
increased hemodynamic load induced by aortic constric-
tion did not affect cardiac hypertrophy, function, and mor-
tality in CKO-NP females (Table S10). Cardiomyocyte
hypertrophic growth during pregnancy was maintained,596 Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc.suggesting that cardiomyocyte hypertrophy induced by
hemodynamic load is not affected in CKO females and
therefore does not appear to be the primary trigger for
PPCM in CKO mice.
STAT3 and Akt signaling are known to promote hyper-
trophy and angiogenesis and to exert protection from ap-
optosis in the heart (Hilfiker-Kleiner et al., 2004a; Jacoby
et al., 2003; Liao, 2004; Negoro et al., 2001) and may there-
fore have overlapping protective functions in the myocar-
dium. Indeed, we observed a late increase in Akt activation
in pregnancy in both genotypes, which was followed by
a postpartum deactivation (Supplemental Data). In con-
trast to Akt, cardiac activation of STAT3 was enhanced in
NT females late in pregnancy and postpartum, at least in
part as consequence of increased peri- and postpartum
serum levels of full-length PRL, because we demonstrated
that PRL stimulation activated STAT3 in the heart in vivo
and in cardiomyocytes in vitro. Taken together, during
pregnancy, elevated Akt activation may ensure physiolog-
ical adaptation of the heart toward pregnancy-related
stress, and this might be sufficient to protect CKO-Prg
females despite the lack of STAT3. In NT-PP females, ac-
tivated STAT3 seems to be sufficient to maintain postpar-
tum cardioprotection; in contrast, the lack of both Akt and
STAT3 activation in CKO-PP is detrimental, indicating that
among several putative mechanisms (including Akt),
STAT3 signaling is necessary for protecting the heart
from development of PPCM.
Oxidative stress is known to rise during pregnancy, cul-
minating in the last trimester, and is paralleled by an in-
crease in total antioxidant capacity (Toescu et al., 2002).
The antioxidant capacity in normal pregnancies peaks in
the postpartum phase, suggesting a need for an efficient
antioxidant defense mechanism postpartum (Toescu
et al., 2002). Circulating levels of oxLDL are markers of ox-
idative stress in patients (Weinbrenner et al., 2003). In con-
trast to normal postpartum women, serum levels of oxLDL
in patients with PPCM were elevated, indicating enhanced
oxidative stress in these patients. Moreover, LVs from
CKO-PP mice display an enhanced production of super-
oxide anions, suggesting that the lack of cardiomyocyte
STAT3 impairs important defense mechanisms against
postpartum-related oxidative stress. Indeed, it has been
shown that MnSOD, a powerful ROS scavenging enzyme,
is under the transcriptional control of STAT3 in cardiomyo-
cytes (Negoro et al., 2001). MnSOD plays a crucial role
in the antioxidant defense of the heart, because only a
50% decrease in MnSOD protein levels in heterozygous
mnsod+/ mice is associated with increased oxidative
damage and cardiomyocyte death (Van Remmen et al.,
2001). Notably, although this reduction of MnSOD protein
levels is associated with subtle alterations in cardiomyo-
cyte mitochondrial functions alone, it is not sufficient to
induce cardiomyopathy under basal conditions (Van
Remmen et al., 2001). Pregnancy/postpartum-associated
stress, however, leads to cardiomyopathy in heterozy-
gous mnsod+/ females (Figure S10). Thus, a 50% reduc-
tion of MnSOD protein appears to be sufficient to cause
peri/postpartum cardiomyopathy. In fact, we observed
that LVs from NT-PP mice showed higher levels of MnSOD
mRNA and proteins than LVs from CKO-PP mice, indicat-
ing a STAT3-dependent transcriptional regulation of
MnSOD in the postpartum heart. In line with a lower oxida-
tive defense, CKO-PP LVs displayed enhanced superox-
ide anion production, which could be prevented with a
pharmacological enhancement of MnSOD-like enzyme
activity by treatment of CKO mice with MnTBAP. In addi-
tion, MnTBAP prevented cardiac dysfunction and post-
partum mortality in CKO mice. Thus, STAT3, via inducing
MnSOD expression, promotes important defense mecha-
nisms against oxidative stress in the postpartum heart.
The PPCM phenotype of our mouse model showed a
degeneration of the cardiac capillary network, which
was prevented by treatment with MnTBAP or by blocking
the release of PRL by BR. It has been shown that oxidative
stress enhances the expression and activation of CD (Cor-
bacho et al., 2002; Roberg and Ollinger, 1998), an enzyme
known to cleave full-length 23 kDa PRL into its antiangio-
genic 16 kDa form (Lkhider et al., 2004). The 16 kDa PRL is
able to dissociate endothelial cell structures, to impair en-
dothelium-dependent vasorelaxation, and to promote
apoptosis in endothelial cells and is considered as a phys-
iological inhibitor of tumor growth (Corbacho et al., 2002;
Gonzalez et al., 2004; Tabruyn et al., 2003). Large quanti-
ties of pituitary PRL are released into the circulation during
lactation (Lkhider et al., 2004), and it has been shown that
cleavage of PRL into the 16 kDa form by CD takes place in
the extracellular compartment of the mammary glands un-
der physiological conditions (Lkhider et al., 2004). Cardiac
levels of active CD protein were markedly increased and
detected in the interstitium of CKO-PP mice. The observa-
tion that active CD released from CD overexpressing
hearts in vivo or from cultured cardiomyocytes released
in vitro processes 23 kDa PRL into its 16 kDa form to-
gether with the finding that PRL cleavage activity could
be blocked by a neutralizing CD antibody in CKO-PP LV
supernatant ex vivo strongly suggest that CD is mainly re-
sponsible for the generation of 16 kDa PRL. In addition,
lowering oxidative stress by MnTBAP prevented the upre-
gulation of activated CD in postpartum CKO females.
Therefore, we postulate that oxidative stress enhances
CD activity and leads to proteolytic cleavage of PRL in
the myocardium of CKO-PP females.
Adenoviral expression of the 16 kDa PRL in the heart
reduced cardiac capillary density and cardiac function in-
dependently of pregnancy and nursing and, indeed, reca-
pitulates aspects of the cardiac phenotype of PPCM. In
contrast to its destructive effect on endothelial cells (Cor-
bacho et al., 2002; Gonzalez et al., 2004; Tabruyn et al.,
2003), the 16 kDa PRL did not affect cardiomyocyte sur-
vival. However, it attenuated cardiomyocyte metabolic
activity and may therefore directly affect cardiomyocyte
function, an aspect that will be evaluated in future studies.
Myocardial injury by CD overexpression after adenoviral
transfection was markedly enhanced in the presence
of high systemic PRL levels due to the generation of16 kDa PRL. Moreover, the systemic toxicity of oxidative
stress induced by doxorubicin treatment was enhanced
in the presence of high systemic PRL levels (Supplemental
Data). Thus, the generation of 16 kDa PRL greatly acceler-
ates cardiac injury caused by oxidative stress and CD. Ac-
cordingly, the blockade of PRL release by BR prevented
the capillary degeneration and the PPCM phenotype in
CKO-BR females. Taken together, we propose that the
generation of the antiangiogenic 16 kDa PRL by CD-
mediated cleavage of the 23 kDa PRL plays a detrimental
role for the cardiac microvasculature and, conceivably,
for cardiomyocyte metabolism (Figure 6).
In contrast to the MnTBAP treatment, which prevented
cardiac capillary degeneration, but not ventricular dilata-
tion, BR provided a more complete rescue of CKO mice
from PPCM, including the prevention of ventricular dilata-
tion and the associated upregulation of MMP3. MMP3 has
been implicated in ventricular dilatation (Tziakas et al.,
2005) and is responsible for a wide range of extracellular
matrix degradation and activation of other MMPs (Mu-
kherjee et al., 2005). PRL via activation of STAT5 is able
to induce MMP3 expression, a process that can be abol-
ished by BR (Nagafuchi et al., 1999). In fact, attenuated
MMP3 expression in CKO-BR mice was associated with
a reduction in STAT5 activation, suggesting that a PRL-
mediated imbalance of STAT transcription factors in the
CKO hearts may, independently from oxidative stress,
contribute to the development of PPCM. Further studies
will be required to test this hypothesis.
Although STAT3 is markedly reduced in the myocar-
dium from patients with PPCM, our data do not provide
information as to whether this reduction of STAT3 is
Figure 6. Schematic Model for the Development of PPCM
In the absence of cardiomyocyte STAT3 activity, the postpartum
expression of MnSOD is attenuated, leading to increased oxidative
stress and the release of CD, which processes 23 kDa PRL into its det-
rimental 16 kDa form. 16 kDa PRL induces endothelial cell apoptosis,
capillary dissociation, and vasoconstriction and impairs cardiomyo-
cyte metabolism, thereby promoting PPCM. Accordingly, BR, a phar-
macologic inhibitor of PRL release, prevents PPCM in mice by de-
creasing circulating PRL.Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc. 597
a primary or a secondary event of PPCM. Nevertheless,
similar to our observation in CKO mice, reduced STAT3
may contribute to the development and/or progression
of PPCM in patients. So far, sequence analysis of the
stat3 gene in the DNA samples from patients with PPCM
and controls did not reveal polymorphisms in the STAT3
gene associated with PPCM (Monika Stoll, personal com-
munication). Our findings of increased CD activity, ele-
vated levels of oxLDL, and 16 kDa PRL in serum samples
of nursing PPCM patients, but not in pregnancy-matched
controls, point to striking similarities between our PPCM
mouse model and human PPCM and are consistent with
the notion that oxidative stress, CD activation, and subse-
quent PRL cleavage may also contribute to the develop-
ment of PPCM in patients. Our encouraging initial results
in a preliminary clinical study with patients treated with
BR, a drug widely used to stop lactation in postpartum
women (Harrison, 1979), are consistent with the hypothe-
sis that PRL and mainly the 16 kDa PRL are causally re-
lated to the development of PPCM in patients. As a limita-
tion of this study, it should be noted that not all effects of
BR on its targets were analyzed and that the inhibition of
PRL secretion is the most plausible reason for the protec-
tive effect of BR in PPCM.
In summary, we show that STAT3 plays a critical role for
the preservation of postpartum myocardial angiogenesis
and function and suggest a central role of STAT3 and
associated signaling pathways in the onset of PPCM (Fig-
ure 6). Importantly, we present evidence for a novel mech-
anism for the development of cardiomyopathy, which
involves the cleavage of PRL into its detrimental 16 kDa
form by CD (Figure 6). BR, a pharmacological inhibitor of
PRL release, prevents PPCM in mice (Figure 6). In conse-
quence, based on our experimental and initial clinical find-
ings, BR may represent a novel therapeutic option to treat
patients with PPCM or to prevent the disease in patients
who suffered and recovered from PPCM in a previous
pregnancy.
EXPERIMENTAL PROCEDURES
PRL (sheep), BR, and all other chemicals were purchased from Sigma.
Cardiomyocyte-Specific Deletion of stat3
The generation of mice with cardiomyocyte-restricted deletion of stat3
has been described (Hilfiker-Kleiner et al., 2004a). Female mice were
first bred at the age of 10–12 weeks, at an age when STAT3 protein
was barely detectable in isolated cardiomyocytes (Figure S2), indicat-
ing that, as in CKO males (Hilfiker-Kleiner et al., 2004a), the Cre-
mediated deletion of stat3 was virtually complete.
Animal Experiments
Generally, analyses were performed 3 weeks after the second delivery.
Prolactin (400 iU/kg) was injected i.v. For chronic administration, os-
motic minipumps (Alzet; PRL 400 iU/kg/d) were implanted in sedated
mice. Adenoviruses, 16K-Ad (Pan et al., 2004), lacZ-Ad, or CD-Ad
(33 108 pfu of each virus) was injected directly into the mouse LV (Sup-
plemental Experimental Procedures). BR (4 mg/kg/d, Novartis) was
added in drinking water. MnTBAB (300 mg/mouse/day) or vehicle (pla-
cebo) was injected subcutaneously. Transthoracic echocardiography598 Cell 128, 589–600, February 9, 2007 ª2007 Elsevier Inc.was performed in sedated mice as previously described (Hilfiker-
Kleiner et al., 2004a). Hemadynamic measurements were assessed
by telemetry (Pelat et al., 2003) or tail cuff in conscious mice or by Millar
catheter in anesthetized mice as described previously (Hilfiker-Kleiner
et al., 2004a, 2004b). For more detailed description of animal experi-
ments, see the Supplemental Experimental Procedures.
All animal studies were in compliance with the Guide for the Care
and Use of Laboratory Animals as published by the U.S. National Insti-
tutes of Health and were approved by our local Institutional Review
Boards.
Patients Data
LV samples were from patients undergoing heart transplantation due
to PPCM (NYHA functional class III or IV) and from donor hearts (NF)
that could not be transplanted for technical reasons. Serum was ob-
tained from PPCM patients (NYHA functional class III or IV) at their first
presentation and from age and pregnancy-matched nursing healthy
woman. oxLDL was determined with a sandwich ELISA kit (Mercodia).
More detailed patient data are presented in the Supplemental Experi-
mental Procedures.
Histological Analyses and Immunostaining
For histological analyses, hearts were fixed in situ, embedded in
paraffin, and stained with picro-Sirus red or H&E, as described (Hil-
fiker-Kleiner et al., 2004a). Interstitial collagen volume fraction was de-
termined in picro-Sirius red-stained sections as described (Hilfiker-
Kleiner et al., 2004a). Apoptotic nuclei were detected by in situ terminal
deoxynucleotidyl transferase-mediated digoxigenin-conjugated dUTP
nick end labeling (TUNEL) and by nuclear morphology using Hoechst
33258 staining (Hilfiker-Kleiner et al., 2004a).
Capillary Density
Capillary density was determined as the ratio of capillaries to 100 car-
diomyocytes in transversely sectioned LV tissue immunostained with
isolectin B4 (Vector) or the platelet-endothelial cell adhesion mole-
cule-1 (PECAM-1) antibody (Santa Cruz) and counterstained with
WGA and Hoechst 33258 as described previously (Hilfiker-Kleiner
et al., 2004a).
Measurement of Myocardial Superoxide
Production and NADH activity
Dihydroethidium fluorescence staining was used for in situ detection of
superoxide production as described (Engberding et al., 2004). NADH
activity was determined in LV myocardium (50 mg protein) by electron
spin resonance (ESR) spectroscopy as described previously (Spieker-
mann et al., 2003). Both methods are described in the Supplemental
Experimental Procedures.
Measurement of Energy-Rich Phosphates in Myocardial Tissue
AMP, ADP, and ATP were measured as described previously (Hilfiker-
Kleiner et al., 2004a). A brief description is provided in the Supplemen-
tal Experimental Procedures.
CD Activity Assay
Supernatant from freshly isolated LV tissue was generated by mincing
LV tissue in ice-cold HBSS. Sedimented minced LV tissue was then in-
cubated in DMEM for 1 hr at 37C and 5% CO2. CD activity was deter-
mined in LV supernatant or in patient serum by using the InnoZyme
CD Immunocapture Activity Assay Kit (Calbiochem) and a FLUOstar
Galaxy.
PRL Cleavage Assay
PRL cleavage activity was assayed in LV supernatant (described
above) by adding citrate/phosphate buffer (pH 3.5) at a 1:1 ratio; sub-
sequently, pepstatin A (2 mg/L) and/or recombinant PRL (0.1 g/L) was
added and mixed and incubated at 37C (5% CO2) for 2 hr. After addi-
tion of an equal volume of Laemmli buffer (5% BME, 0.2% DTT),
samples were assayed by immunoblotting. For depletion of CD pro-
tein, LV supernatant was incubated with a CD neutralizing antibody
(Nr. 06-467, Upstate) and subsequently protein A-agarose (Roche) to
sediment and remove CD from supernatant.
Real-Time PCR and Immunoblot Analyses
Real-time measurements of PCR amplification were performed by us-
ing the Stratagene MX4000 multiplex QPCR System using the SYBR
green dye method (Brilliant SYBR Green Mastermix-Kit, Stratagene)
as described (Klein et al., 2005). Primer sequences are listed in the Sup-
plemental Experimental Procedures. Protein expression levels were
determined by western blotting according to standard procedures;
antibodies are listed in the Supplemental Experimental Procedures.
Statistical Analyses
Data are presented as mean ± SD. Differences between groups were
analyzed by Mann-Whitney test, log-rank test, Student’s t test, or
ANOVA followed by Bonferroni as appropriate. A two-tailed p value
of <0.05 was considered to indicate statistical significance.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, ten figures, and ten tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/3/589/DC1/.
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